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Background: Exacerbation history is used to grade the risk of COPD exacerbation, but 
its reliability and relationship to other risk factors and prior therapy is unclear. To examine 
these interrelationships, we conducted a post hoc analysis of patients in the TIOSPIR trial 
with 2 years’ follow-up or who died on treatment.
Patients and methods: Patients were grouped by their annual exacerbation rate on treatment 
into nonexacerbators, infrequent, and frequent exacerbators (annual exacerbation rates 0, 1, 
and 1, respectively), and baseline characteristics discriminating among the groups were deter-
mined. We used univariate and multivariate analyses to explore the effect of baseline character-
istics on risk of exacerbation, hospitalization (severe exacerbation), and death (all causes).
Results: Of 13,591 patients, 6,559 (48.3%) were nonexacerbators, 4,568 (33.6%) were infre-
quent exacerbators, and 2,464 (18.1%) were frequent exacerbators; 45% of patients without 
exacerbations in the previous year exacerbated on treatment. Multivariate analysis identified 
baseline pulmonary maintenance medication as a predictive factor of increased exacerbation 
risk, with inhaled corticosteroid treatment associated with increased exacerbation risk irrespec-
tive of exacerbation history.
Conclusion: Our data confirm established risk factors for exacerbation, but highlight the limita-
tions of exacerbation history when categorizing patients and the importance of prior treatment 
when identifying exacerbation risk.
Keywords: COPD, exacerbation, frequent exacerbators
Plain-language summary
Patients with COPD may experience times when symptoms suddenly get worse, known as 
exacerbations. These events contribute to progression of the disease, and make patients feel 
worse. People who have had a lot of exacerbations in the past are most at risk of having more 
exacerbations. In this study, researchers looked at what factors other than the number of past exac-
erbations might predict which patients are most likely to have an exacerbation. The researchers 
used results from a clinical trial that included more than 17,000 patients with COPD who were 
followed for 2–3 years. The results showed that in addition to history of exacerbation, the 
medications that patients were prescribed before they entered the trial also predicted how likely 
they were to have an exacerbation. This is probably because patients who are not doing well 
and most at risk of having an exacerbation are more likely to be prescribed certain medications. 
Overall, this study confirms that patients who have had more exacerbations in the past are at 
greater risk of exacerbations in the future, and shows that patients who require more medica-
tions for their COPD are at higher risk of exacerbations.
Introduction
Exacerbations of symptoms sufficient to warrant treatment with antibiotics 
and/or systemic corticosteroids (CSs) and/or hospitalization contribute to health-status 
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impairment and disease progression in patients with COPD.1,2 
Multiple reports in different COPD populations have found 
that exacerbations are more likely if the patient reports previ-
ous events, is more breathless, and has poor lung function,3–5 
although the importance of a history of chronic bronchitis as 
a predictor of exacerbations is less clear.5,6 The data identify-
ing these risk factors for exacerbations derive largely from 
observational cohorts or database studies where treatment 
choices reflect routine clinical practice.
To date, relatively little attention has been paid to the 
relationship of baseline treatment to the risk of subsequent 
exacerbation of COPD. Extensive randomized controlled 
trial data show that inhaled long-acting muscarinic antago-
nists (LAMAs), long-acting β
2
-agonists (LABAs), and 
LABA–inhaled CS (ICS) combinations reduce the risk of 
exacerbations.7–9 Further studies have shown that LAMAs are 
more likely to be effective than LABAs in preventing exac-
erbation, irrespective of whether LABA is administered once 
daily10 or twice daily.11 Whether the same risk factors operate 
when all patients are treated with these drugs is not yet clear. 
Moreover, it is not known whether treatment intensity, which 
is often used as a surrogate for disease severity in patients 
with asthma,12 is a marker of disease severity in COPD.
To address these problems, we examined data from 
the TIOSPIR trial,13,14 the largest long-term, randomized, 
double-blind, double-dummy, parallel-group trial in patients 
with COPD performed to date. We wished to establish 
whether use of LABAs and ICSs could be used as a surro-
gate marker for increased exacerbation risk in patients with 
COPD treated with tiotropium. We also sought to examine 
whether clinical and demographic variables that have been 
shown to be risk factors for exacerbations would pertain 
to a large international COPD population using tiotropium 
maintenance therapy.
Patients and methods
study design
In TIOSPIR, 17,135 patients with COPD were randomized 
and treated in a double-blind, parallel-group, event-driven 
trial with follow-up of 2–3 years. Patients were randomized 
to once-daily tiotropium Respimat 5 or 2.5 μg, or once-daily 
tiotropium HandiHaler 18 μg (both Boehringer Ingelheim, 
Ingelheim am Rhein, Germany). The trial design and meth-
odology have been published previously.13 TIOSPIR was per-
formed in accordance with the provisions of the Declaration 
of Helsinki, and the study protocol and procedures were 
approved by relevant institutional review boards and ethics 
committees (independent ethics committee Johns Hopkins 
Medicine Institutional Review Board, Baltimore, MD, USA). 
All the patients provided written informed consent.
study population
All participants had a diagnosis of COPD with a postbroncho-
dilator forced expiratory volume in 1 second (FEV
1
) 70% 
predicted, an FEV
1
:forced vital capacity (FVC) ratio 0.7, 
were aged 40 years, had been clinically stable for at least 
6 weeks, and had 10 pack-years of smoking history. 
Patients with concomitant cardiac disease were included, 
unless they had a recent history of myocardial infarction, car-
diac arrhythmia, or hospitalization for heart failure. Patients 
were excluded if they had a history of significant respiratory 
diseases other than COPD, including asthma.
assessments
The study period was dependent on the number of fatal events 
observed (event-driven trial). Visits occurred at weeks 0, 6, 
and 12, and then every 12 weeks for the duration of the trial. 
At the first visit, concomitant medication use and medical 
history were noted, as was exacerbation history. Hospital-
ization due to COPD in the year prior to enrolment was not 
collected. At all visits, information about exacerbations and 
their treatment, including the need for hospitalization, were 
recorded. Vital status during the trial period was obtained in 
99.7% of participants. Causes of death were adjudicated by 
an independent mortality adjudication committee.
COPD exacerbations were defined as a worsening of 
two or more major respiratory symptoms (dyspnea, cough, 
sputum, chest tightness, or wheezing) lasting 3 days and 
requiring specified treatment changes. Moderate exacerba-
tions required a prescription for antibiotics, systemic CSs, or 
both (with no hospitalization); severe exacerbations required 
hospitalization. Fatal COPD exacerbations were those with 
fatal outcome. The onset of exacerbation was defined as the 
onset of the first reported symptom; the end of exacerbation 
was decided by the investigator, based on clinical judgment 
(GOLD grouping was determined according to 2011 guide-
lines, which classified patients’ risk by airflow limitation, 
symptoms, and exacerbations).15
statistical analysis
The tiotropium-treatment arms were pooled for this post hoc 
analysis, as there were no differences between treatments 
for the primary outcomes (exacerbations and mortality).14 
Patients were categorized by their annual exacerbation rate 
on treatment into the following frequency groups: nonex-
acerbators, infrequent exacerbators (annual exacerbation 
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rate 0 and 1), and frequent exacerbators (annual exacer-
bation rate 1). Patients were also categorized by the number 
of reported prestudy exacerbations (exacerbation history 0, 1, 
and 1 in the year before the study). In addition, we analyzed 
patients with severe exacerbations (exacerbations associated 
with hospitalization) and those with a fatal exacerbation.
Baseline characteristics discriminating between patients 
in the exacerbation groups (either prestudy or on treat-
ment) were identified using descriptive statistics (differ-
ences between groups were signified by nominal P-values 
established using the Kruskal–Wallis test and the χ2 test). 
Furthermore, prognostic characteristics of exacerbation, hos-
pitalization due to COPD exacerbation, and death (all-cause) 
were identified by univariate and multivariate Cox regression 
analyses, with results shown as forest plots.
The importance of factors added to the models was 
assessed by means of likelihood ratio tests. The effect of 
exacerbation history, LABA, and ICS use at baseline on 
exacerbations and death was investigated by Cox regres-
sion models with covariates for postbronchodilator FEV
1
 
and smoking status at baseline. Time to event according to 
exacerbation history and ICS use at baseline are shown as 
Kaplan–Meier plots. To ensure that there was sufficient time 
for recurrent events to occur, we restricted the analysis to 
individuals with 2 years of clinical observation (follow-up) 
or who had died within that period.
Results
study population
Of the 17,135 patients who received tiotropium, 13,591 were 
followed for 2 years or died during the study. In this group, 
6,559 (48.3%) had no exacerbations during the trial, 4,568 
(33.6%) were infrequent exacerbators (annual exacerbation 
rate 0 and 1), and 2,464 (18.1%) were frequent exacerba-
tors (annual exacerbation rate 1). A severe exacerbation 
requiring hospitalization was reported in 2,002 (14.7%) of 
these patients, and 120 (0.9%) patients experienced a fatal 
exacerbation (Table 1, continued in Table S1). In the year 
before randomization, 7,022 (51.7%) patients had no exac-
erbations, 3,902 (28.7%) had one exacerbation, and 2,667 
(19.6%) had more than one exacerbation (Table S2).
risk factors by exacerbation frequency 
and severity (hospitalized and fatal 
exacerbation)
Baseline demographics
Baseline characteristics, including smoking history and body-
mass index (BMI), were similar among the different groups 
whether defined by exacerbation rate on treatment (Table 1) 
or pretreatment (number of exacerbations reported in the 
preceding year; Table S2). The proportion of female patients 
was highest in the frequent-exacerbator group compared with 
the other exacerbation groups. Patients aged 60 years had 
more exacerbations on treatment than patients 60 years of 
age (Table 1), although patients aged 60 years were more 
likely to report no exacerbation in the year prior to the trial 
compared with younger (60 years) patients (Table S2). 
Patients most likely to have a fatal exacerbation were male 
and 70 years old (Table 1, Figure 1).
Baseline lung function, exacerbation history, and 
COPD symptoms
Baseline spirometry and exacerbation history showed a 
gradation across the on-treatment exacerbation-frequency 
group (being worst in frequent exacerbators), as did GOLD 
staging (I–IV), GOLD grouping (A–D), and breathlessness 
(Table S1). However, 13% of patients without a pretreatment 
exacerbation in the year before the study became frequent 
exacerbators during the trial (Figure 2). The presence of 
sputum-producing cough (chronic bronchitis for 3 months 
over 2 years) was consistent across these groups. When 
patients were classified according to their history of exac-
erbations before study entry, a similar demographic pattern 
was seen (Table S2); however, those reporting previous 
exacerbations were more likely to have a history of sputum-
producing cough. Patients who experienced severe exacerba-
tions showed poorer lung function, were more likely to be 
GOLD stage IV and group D, and had more breathlessness 
than frequent on-treatment exacerbators. In patients with 
fatal exacerbations, this pattern was even more pronounced 
(Table 1, Table S1).
Baseline cardiovascular history and medication
In general, there were no differences between the on-
treatment and prestudy frequency groups in either their 
history of cardiovascular events or their use of cardiovascular 
medications (Table 1, Table S3). However, heart failure was 
present at study entry more often among those dying from 
an exacerbation.
Baseline risk factors for exacerbation, 
hospitalization (due to COPD), and death 
(all-cause)
risk of exacerbation
Overall, univariate analysis identified the same baseline char-
acteristics associated with differences in risk for exacerbation 
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as the descriptive analysis (Figure S1A). Multivariate 
analysis adjusted for all other relevant covariates indicated 
that modified Medical Research Council scale breathless-
ness score, exacerbation history, airflow limitation (FEV
1
% 
predicted), and LABA or ICS use at baseline (the surrogate 
marker for maintenance therapy) are the most important risk 
factors (Figure 1A).
Even after adjustment for all other important risk 
factors, baseline maintenance therapy with LABAs and 
ICSs remained relevant factors improving the model fit 
(P0.0001) (Table 2). The surrogate marker LAMA use 
could not be evaluated, as patients on LAMAs at baseline did 
not add an additional treatment during the study compared 
with those receiving LABAs or ICSs at baseline.
risk of hospitalization due to COPD
Similar risk predictors as those for exacerbations were 
observed for hospitalization due to COPD, with the addition 
of poor FVC (Figure S1B). Multivariate analysis identi-
fied breathlessness score, exacerbation history, FEV
1
% 
predicted, ICS use at baseline (surrogate marker), and 
cardiac history as the most important factors; however, the 
analysis did not confirm the independent risk-modifying 
effect of FVC (Figure 1B). After adjustment for other risk 
??? ?
??????????
????????????????????? ????????????????????? ?????????????????????
??????????? ?????????? ??????????? ?????????? ???????????
?? ??? ? ?? ??? ? ??
?? ?????????????????????? ?? ???????????????????? ?? ?????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????
????????????????????????
??????????????????????????????????????????????????? ?????? ???????
????????????????? ?????????
???????????????
??????????????????????????????????????
?????????
?????????
????????????????????????????
?????????????????????????????????????
?????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????
???????????????????????????????????????????????
? ? ?
Figure 1 Multivariate Cox regression of time to (A) first exacerbation, (B) first hospitalization due to COPD exacerbation, and (C) death (treated set).
Notes: Multivariate analyses performed separately for A, B, and C, and not all variables qualified for all three analyses, hence not all variables included in final models. mMRC 
breathlessness descriptions: 0, not troubled with breathlessness except with strenuous exercise; 1, troubled by shortness of breath when hurrying on the level or walking up 
a slight hill; 2, walks more slowly than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3, stops 
for breath after walking about 100 yards [91.44 m] or after a few minutes on the level; 4, too breathless to leave the house or breathless when dressing or undressing.
Abbreviations: aus, australia; BMI, body-mass index; euro, europe; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICs, inhaled corticosteroid; 
laBa, long-acting β2-agonist; mMRC, modified Medical Research Council; NZ, New Zealand.
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factors, baseline maintenance therapy with LABAs and ICSs 
remained relevant factors for time to hospitalization due to 
COPD, improving the model fit (P0.0001) (Table 2).
risk of death (all-cause)
With respect to mortality, significant predictors included 
sex, age, BMI, breathlessness score, exacerbation history, 
lung function (FEV
1
% predicted and FVC), and history of 
cardiac events (Figure S1C). With the exception of FVC, 
these factors were confirmed by multivariate analysis, 
indicating that underweight male patients were at increased 
risk of dying, and this risk increased with age, reduced lung 
function, and exacerbation frequency.
effect of exacerbation history and 
baseline pulmonary therapy on 
exacerbation, hospitalization, and death
risk of exacerbation
When analyzing the risk-modifying effect of exacerbation 
history and baseline LABA/ICS use on exacerbation (analysis 
adjusted for smoking status and postbronchodilator FEV
1
 at 
baseline), patients with a history of frequent exacerbations 
(annual exacerbation rate 1) were at significantly higher 
risk of exacerbations during the trial. This higher risk of 
exacerbations for frequent exacerbators was irrespective 
of their LABA or ICS use at baseline (P0.0001) versus 
nonexacerbators (Table 3A). Nevertheless, use of ICSs at 
baseline was a marker for increased risk of further exacer-
bations in patients with and without exacerbation history. 
Overall, patients receiving ICS or LABA therapy did not 
show a lower exacerbation risk than patients without ICS or 
LABA use at baseline (Table 3A). Kaplan–Meier analysis 
of time to first exacerbation showed that patients without an 
exacerbation history who used ICSs at baseline had a similar 
risk of exacerbation as patients with previous exacerbations 
without ICS use (Figure 3A).
risk of hospitalization due to COPD
Kaplan–Meier analysis of time to hospitalization showed that 
the ICS-use marker and a history of more than one exacerba-
tion were associated with increased risk of hospitalization 
(Figure 3B).
risk of death (all-cause)
Patients receiving ICSs/LABAs at baseline were not at an 
increased risk of mortality during the trial compared with 
patients not receiving the combination, irrespective of exacer-
bation history (Table 3B). Similarly, patients receiving ICSs 
or LABAs did not have a lower risk of mortality compared 
with patients not receiving ICSs or LABAs, respectively 
(Table 3B). Patients with an exacerbation history receiving 
ICSs plus LABAs were, however, at an increased risk of 
mortality compared with those without a history of exacerba-
tions. Therefore, past exacerbations warranting ICS/LABA 
use are an indicator for increased risk of death (Table 3B). 
Kaplan–Meier analysis of time to death showed that ICS use 
Figure 2 exacerbation rate during the trial by pretreatment exacerbation history.
Notes: In patients with 2 years of follow-up or who died during the study. 
Patients with frequent exacerbations could also have a fatal exacerbation or a 
severe (hospitalized) exacerbation. Pretreatment exacerbations were defined as 
the number of exacerbations occurring in the year prior to the trial, based on the 
number of episodes treated with antibiotics and/or systemic corticosteroids.
??
??
??
??
??
??
? ?????????????? ???????????????????
??????????????????????????????????
???
????
????
?
????????????????????????????????????
??????????????????????????????
?????????????????????????????
?????????????????????????????
Table 2 likelihood-ratio test for baseline maintenance therapies
Endpoint df χ2 P-value
Time to first exacerbationa
laBa use at baseline 1 234.7 0.0001
ICs use at baseline 1 259.74 0.0001
Time to hospitalization due to COPDb
laBa use at baseline 1 67.74 0.0001
ICs use at baseline 1 91.66 0.0001
Time to deathc
laBa use at baseline 1 0.0003 0.9867
ICs use at baseline 1 0.0478 0.8269
Notes: aIncludes sex, age, body-mass index, region, duration of COPD (years), 
COPD episodes treated in last year, gOlD stage, FVC-predicted gOlD stage-like 
class (eCsC, Caucasian), cardiac history, and mMrC scale; bincludes age, body-mass 
index, smoking status, smoking history (pack-years), race, region, sputum-producing 
cough, COPD episodes treated in last year, gOlD stage, cardiac history, and 
mMrC scale; cincludes sex, age, body-mass index, smoking status, smoking history 
(pack-years), region, COPD episodes treated in last year, gOlD stage, baseline 
cardiac medication, cardiac history, and mMrC scale.
Abbreviations: eCsC, european Community for Coal and steel; FVC, forced vital 
capacity; ICs, inhaled corticosteroid; laBa, long-acting β2-agonist; mMRC, modified 
Medical research Council.
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and a history of more than one exacerbation were associated 
with increased risk of death (Figure 3C).
stability of exacerbation phenotype
In the first year, 11,885 patients were infrequent exacerba-
tors (0–1 exacerbation). Of these, 10,953 (92.2%) were also 
infrequent exacerbators in the second year. However, of the 
1,706 patients with two or more exacerbations in the first 
year (frequent exacerbators), 1,023 (60%) were infrequent 
exacerbators in the second year.
Discussion
Identifying patients at greatest risk of exacerbation should 
facilitate the clinical management of COPD. In this large 
population of patients who were initially clinically stable and 
whose therapy always included the LAMA tiotropium, we 
found a similar risk profile to that reported in other groups 
where therapy was less standardized. Important factors 
included history of prior exacerbations, more dyspnea, poor 
lung function, and female sex. Medication use at baseline 
represented an independent risk of future exacerbation, but 
was not as important as exacerbation history in identifying 
those at risk of hospitalization or death. These data have 
implications for how we evaluate COPD patients already 
receiving treatment.
Unlike earlier studies, TIOSPIR participants all received 
a LAMA via either HandiHaler or Respimat, but in addition 
could continue with any non-LAMA therapy. The resulting 
population would be one that would occur if the health-care 
provider followed recommendations for treatment of current 
GOLD groups B–D.16 Standardizing therapy in this way did 
not change the relative contribution of predictive factors 
associated with exacerbations.
There was no difference in age, smoking status, or BMI 
category between individuals with frequent events and those 
who never experienced an exacerbation over the 2 years of 
follow-up. As in the ECLIPSE study,5 a history of sputum-
producing cough in our patients did not predict those more 
likely to exacerbate. This difference from the data reported 
in COPDGene participants17 and other studies18 may reflect 
differences in the definition of chronic bronchitis that is 
used: studies that did not use the classic definition of chronic 
bronchitis were more likely to identify an association between 
chronic cough and exacerbation frequency.19,20 Neither a 
history of cardiac disease nor cardiac medication use distin-
guished the exacerbation groups (grouped by exacerbation 
frequency and severe and fatal exacerbation), suggesting 
that in this population most events were driven by respira-
tory rather than cardiac causes. As in earlier reports, both 
postbronchodilator FEV
1
 and dyspnea intensity were related 
to exacerbation frequency. However, there was consider-
able overlap between subgroups, with a third of frequent 
exacerbators having a modified Medical Research Council 
grade 1 at baseline.
When the effect of relevant covariates (postbronchodi-
lator FEV
1
 and smoking status at baseline) was controlled 
for, the same relationships for exacerbation frequency and 
time to first exacerbation held true; this was also the case 
for time to hospitalization and death. Sex was an exception, 
where females were more likely to experience exacerbations, 
but less likely to die. This paradoxical finding has been 
noted previously, and no satisfactory explanation currently 
exists for this anomaly.21 However, it has been suggested 
that women are more often underdiagnosed, show lower 
adherence to treatment than men, and present with fewer 
comorbidities.22
A history of exacerbations (in the year before the study) 
was a powerful explanatory variable, with evidence of a 
dose–response effect for time to first exacerbation and time 
to hospitalization, although less evident for time to death. 
However, the use of exacerbation history as a categorical 
variable in individual patients as proposed by GOLD (“0 or 1 
indicates low risk, while 2 or more exacerbations indicate 
high risk”) was rather disappointing.16 Overall, 55% of 
patients remained exacerbation-free if they had no exacerba-
tion in the year before the study, while 45% did not, despite 
all of them using at least a LAMA. Additionally, 13% of 
patients without exacerbation history became frequent exac-
erbators, and 36% of frequent exacerbators before the study 
had no exacerbations during the study.
ECLIPSE noted that patients did shift from high-risk to 
low-risk exacerbator groups over time, and the reasons for 
doing so were unclear.23 Recently, Han et al made similar obser-
vations regarding the instability of the frequent-exacerbator 
phenotype in the SPIROMICS cohort.24 However, adequate 
therapy seems to improve the ratio of infrequent to frequent 
exacerbators over time.25–27 Our data emphasize that patients 
with COPD have the propensity to exacerbate during the 
course of their disease, and that prior exacerbation history 
is only an approximate guide as to what will happen subse-
quently, not a precise predictor of exacerbation risk. As all 
our patients received the same COPD maintenance therapy 
on treatment, other factors may also be relevant for changes 
in risk over time.
The use of a maintenance respiratory therapy, such as a 
LABA, LAMA, or ICS, is usually considered in terms of the 
ability of that treatment to prevent exacerbations, rather than 
as a marker of the likelihood that they will occur. However, 
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Figure 3 Time to first exacerbation (A), hospitalization (B) or death (C) according to exacerbation rate in the year preceding the trial and ICs use at baseline.
Abbreviation: ICs, inhaled corticosteroids.
prior use of certain treatments, especially ICSs, which are 
almost exclusively prescribed as a way to prevent exacer-
bations, has been shown to identify patients more likely to 
exacerbate,28 a finding supported by clinical trial data where 
prior ICS users had a higher exacerbation rate postrandomiza-
tion.29 Our data suggest that both LABA and ICS use predicts 
a higher rate of subsequent exacerbations, and that this is true 
irrespective of the previous exacerbation rate. Nevertheless, 
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this only applied to the risk of a health-care utilization-
defined exacerbation. This relationship might mean that 
therapy increased the risk of exacerbations, although this 
is unlikely given the wealth of randomized controlled data 
suggesting the opposite.30,31 A more likely explanation is that 
patients are given these drugs to prevent exacerbations and/or 
because they are believed to be progressing less well, and 
thus are more likely to relapse in future, irrespective of any 
positive effect of their therapy. Hospitalizations and death 
were related to exacerbation history, but not medication use.
Our study has strengths and limitations. Although not 
as large as the recent UK database study,28 exacerbations 
were prospectively defined and collected. We considered 
data over a potential 2-year follow-up period in a substantial 
number of patients, and had a near-complete assessment of 
vital status. The universal use of LAMA therapy allowed 
us to not just assess how this treatment option related to 
exacerbation outcomes but also how the use of other treat-
ments interacted with LAMA use. However, these treatments 
were not randomized and reflected the treatment choices of 
clinicians. We did not evaluate the surrogate marker LAMA 
use at baseline. Patients on LAMAs prior to the study simply 
remained on them, unlike patients receiving LABAs or ICSs 
at baseline, who had a LAMA added to their therapy. This 
analysis would thus show the benefit of adding a LAMA, 
rather than the risk of being on a LAMA. In addition, bio-
marker data were not included, which some have suggested 
are associated with more events,32 although these are not 
routinely recorded. Furthermore, when describing associa-
tions between current treatment and future risk, there is the 
limitation that the characteristics of patients at the time of 
prescription are not known, nor is the effect of the treatments 
on these characteristics.
Our data have some clinical implications. The similarity 
of the risk profile in our patients to those reported in groups 
where treatment was less rigidly controlled not only supports 
attempts to predict the inherent likelihood of exacerbation,33 
but also supports the idea of an “exacerbator phenotype” and 
its use as a way to stratify future risk. However, reliance on 
exacerbation history alone can be misleading, and factors 
other than those commonly assessed, and specifically prior 
and/or current therapy, should be considered when assessing 
the likelihood of the individual patient experiencing future 
exacerbations. The additional role of treatment as a marker of 
the propensity to exacerbate resembles the situation in asthma, 
where treatment steps are commonly linked to the therapy 
already prescribed. Whether a similar system can be devel-
oped for COPD patients will be for others to determine.
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Table S2 Patient baseline characteristics according to the number of exacerbations in the year preceding the trial
Baseline characteristics No exacerbation in year 
prior to study (n=7,022)
One exacerbation in year 
prior to study (n=3,902)
More than one exacerbation in 
year prior to study (n=2,667)
Days on treatment (median) 842 840 840
sex
Male 5,073 (72.2) 2,791 (71.5) 1,888 (70.8)
region
asia
Europe/Africa/Australia/NZ
latin america
north america
866 (12.3)
3,692 (52.6)
305 (4.3)
2,159 (30.7)
515 (13.2)
2,394 (61.4)
306 (7.8)
687 (17.6)
374 (14)
1,735 (65.1)
173 (6.5)
385 (14.4)
age (years)
60
60–70
70
1,918 (27.3)
2,832 (40.3)
2,272 (32.4)
1,152 (29.5)
1,547 (39.6)
1,203 (30.8)
850 (31.9)
1,010 (37.9)
807 (30.3)
BMI (kg/m2), mean (sD) 26.6 (5.7) 26.2 (5.6) 26.2 (5.6)
Duration of COPD (years), mean (sD) 6.9 (5.9) 7.3 (6) 8.7 (6.7)
smoking history (pack-years), median 40 40 36
Current smoker 2,771 (39.5) 1,431 (36.7) 1,002 (37.6)
Postbronchodilator FeV1% predicted, mean (sD) 49.8 (13.5) 47.8 (13.5) 46.2 (14.2)
Postbronchodilator FVC (l), mean (sD) 2.798 (0.85) 2.692 (0.827) 2.644 (0.836)
Postbronchodilator FeV1/FVC, mean (sD) 0.505 (0.111) 0.499 (0.114) 0.489 (0.119)
gOlD stage
I
II
III
IV
16 (0.2)
3,646 (51.9)
2,647 (37.7)
612 (8.7)
3 (0.1)
1,785 (45.7)
1,668 (42.7)
410 (10.5)
6 (0.2)
1,124 (42.1)
1,122 (42.1)
378 (14.2)
gOlD groupa
a
B
C
D
2,042 (29.1)
1,425 (20.3)
1,298 (18.5)
1,856 (26.4)
856 (21.9)
880 (22.6)
697 (17.9)
1,351 (34.6)
0
0
868 (32.5)
1,760 (66)
Pulmonary medication use 6,291 (89.6) 3,626 (92.9) 2,453 (92)
laMa 3,426 (48.8) 1,773 (45.4) 1,187 (44.5)
laBa 4,139 (58.9) 2,468 (63.2) 1,742 (65.3)
ICs 3,816 (54.3) 2,421 (62) 1,749 (65.6)
CV-medicationb use 3,651 (52) 2,010 (51.5) 1,332 (49.9)
mMrC breathlessness score
0
1
2
3
4
792 (11.3)
2,906 (41.4)
2,303 (32.8)
921 (13.1)
99 (1.4)
229 (5.9)
1,425 (36.5)
1,570 (40.2)
615 (15.8)
61 (1.6)
96 (3.6)
811 (30.4)
1,122 (42.1)
578 (21.7)
60 (2.2)
sputum-producing cough 3 months over 2 years 3,964 (56.5) 2,743 (70.3) 2,050 (76.9)
Medical history of stroke 176 (2.5) 81 (2.1) 56 (2.1)
Medical history of MI 444 (6.3) 198 (5.1) 144 (5.4)
Medical history of IhD/CaD 987 (14.1) 632 (16.2) 488 (18.3)
Medical history of cardiac arrhythmia 722 (10.3) 418 (10.7) 277 (10.4)
Medical history of heart failure 399 (5.7) 389 (10) 341 (12.8)
Notes: agOlD grouping (a–D) was performed post hoc based on gOlD 2013 criteria, as hospitalizations in past year were not collected; bincludes β-blockers, calcium-
channel blockers, cardiac glycosides (digoxin), angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, nitrates, antiarrhythmics class I or III (sodium- or 
potassium-channel blockers), adenosine, acetylsalicylic acid, antiplatelets, anticoagulants, vitamin K antagonists, direct thrombin inhibitors, and factor Xa inhibitors. Data are 
n (%) unless otherwise stated. The maximum proportion of missing data at baseline was below 0.2%, except for race (4%) (missing data not shown).
Abbreviations: BMI, body-mass index; CaD, coronary artery disease; CV, cardiovascular; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICs, inhaled 
corticosteroid; IhD, ischemic heart disease; laBa, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; MI, myocardial infarction; mMRC, modified Medical 
Research Council; NZ, New Zealand.
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exacerbator subtypes in TIOsPIr
Figure S1 Univariate Cox regression of time to first (A) exacerbation, (B) first hospitalization due to COPD exacerbation and (C) death (treated set).
Notes: Breathlessness mMrC descriptions: 0, not troubled with breathlessness except with strenuous exercise; 1, troubled by shortness of breath when hurrying on the 
level or walking up a slight hill; 2, walks more slowly than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace 
on the level; 3, stops for breath after walking about 100 yards [91.44 m] or after a few minutes on the level; 4, too breathless to leave the house or breathless when dressing 
or undressing.
Abbreviations: aus, australia; BMI, body-mass index; euro, europe; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICs, inhaled corticosteroid; 
laBa, long-acting β2-agonist; mMRC, modified Medical Research Council; NZ, New Zealand.
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